BsAb regimens achieve high remission rates in lymphomas, suggesting a shift in therapy expectations for patients.
BsAbs represent a major advance in B-NHL, offering high rates of deep remission with predictable safety and outpatient feasibility. As trial data continues to mature, BsAb-based regimens are poised to become foundational across multiple lines of therapy, reshaping expectations for patients with both aggressive and indolent lymphomas.
No takes yet. Share an insight, caveat, or question.
Jhaveri et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: